ELVN Stock — Enliven Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$57.86

Market cap

$4.24B

Price action

19 metrics

Price change (1W)

-5.2%

Price change (30D)

-0.3%

Price change (3M)

+62.9%

Price change (6M)

+101.3%

Price change (YTD)

+275.7%

Price change (1Y)

+185.4%

Trailing year

Price change (5Y)

+203.9%

52-week high

$61.15

52-week low

$15.14

Change from 52-week high

-5.4%

Change from 52-week low

+282.2%

Annualized volatility

79.9%

Beta

1.0

RSI (14D)

50.7

Price vs SMA 50

+5.2%

Price vs SMA 200

+56.1%

Avg volume (3M)

1.43M

Relative volume

0.7

Average dollar volume

$71.20M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

73.27M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

4.7

reciprocal yield 21.1%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-2.5%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-05-27

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$124.41M

Net income (TTM)

−$105.93M

Trailing 12 months

Diluted EPS (TTM)

$-1.64

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-69.53

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+27.0%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-11.8%

Return on assets

-11.6%

Debt / equity

—

Current ratio

64.1

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

64.1

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$895.15M

Latest balance sheet

Cash & equivalents

$135.50M

Total assets

$910.22M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$66.94M

Capital expenditures (TTM)

—

R&D (TTM)

$89.15M

SG&A (TTM)

—

Stock compensation (TTM)

$40.81M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

213

13F filer change QoQ

+39

Institutional ownership

109.7%

Short interest

3 metrics

Short interest

11.3%

Latest settlement · 6.3 days to cover

Days to cover

6.3d

Short-squeeze score

77 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$63.80M

Insider-sentiment score

19 / 100

Risk flags

1 metrics

Going concern

—

ELVN · Enliven Therapeutics, Inc.

ELVN metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search